Laval, Canada
Ananda Devices, founded in 2015 and headquartered in Canada, operates at the intersection of Biotechnology and Manufacturing. The company is pioneering advancements in drug development through its proprietary Neuron-on-a-chip technology. By offering high-throughput systems, Ananda Devices allows for faster drug development, improved toxicity screenings, and enhanced disease modeling.
With a commitment to reducing animal testing, the company emphasizes creating 100% human-based models, enhancing the physiological relevance of experiments. This approach not only streamlines research processes but also aligns with ethical standards growing in priority across the scientific community.
The last recorded funding event for Ananda Devices was a grant investment on 16 August 2024. Though specific investors were not disclosed, the infusion of capital underscores confidence in their innovative platform to revolutionize drug development processes.
